Related Experiment Video

Updated: Dec 29, 2025

Development of a Human Preclinical Model of Osteoclastogenesis from Peripheral Blood Monocytes Co-cultured with Breast Cancer Cell Lines
06:00

Development of a Human Preclinical Model of Osteoclastogenesis from Peripheral Blood Monocytes Co-cultured with Breast Cancer Cell Lines

Published on: September 13, 2017

7.5K

c-MET as a Potential Resistance Mechanism to Everolimus in Breast Cancer: From a Case Report to Patient Cohort

Valentin Van den Bossche1, Gaspard Jadot1, Guillaume Grisay1

  • 1Medical Oncology Unit, Hopital de Jolimont, Rue Ferrer 159, 7100, Haine Saint Paul, Belgium.

Targeted Oncology
|February 6, 2020
PubMed
Abstract

Insights

Increased c-MET expression in breast cancer patients correlates with resistance to everolimus. Targeting c-MET with cabozantinib shows promise, suggesting c-MET as a predictive biomarker for everolimus efficacy.

Area of Science:

  • Oncology
  • Molecular Biology
  • Translational Research

Background:

  • Everolimus is a targeted therapy for breast cancer.
  • Understanding resistance mechanisms is crucial for optimizing treatment.
  • c-MET signaling is implicated in various cancers.

Observation:

  • A patient with breast cancer developed high c-MET expression after progression on everolimus.
  • This patient showed a significant response to cabozantinib, a c-MET inhibitor.
  • In a cohort study, baseline c-MET positivity was linked to aggressive tumor features.

Findings:

  • c-MET expression increased during everolimus treatment, indicating a role in resistance.
  • c-MET-positive breast cancer patients had shorter progression-free survival and lower response rates to everolimus.
  • Baseline c-MET expression was associated with higher tumor grade, visceral metastases, and lower endocrine sensitivity.

Implications:

  • c-MET may serve as a predictive biomarker for everolimus efficacy in breast cancer.
  • Inhibition of c-MET, potentially with cabozantinib, warrants further investigation in breast cancer treatment.
  • This study opens avenues for personalized treatment strategies based on c-MET status.

More Related Videos

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

9.1K
Using Mouse Mammary Tumor Cells to Teach Core Biology Concepts: A Simple Lab Module10:39

Using Mouse Mammary Tumor Cells to Teach Core Biology Concepts: A Simple Lab Module

Published on: June 18, 2015

13.8K

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.5K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.6K